News
CODX
0.3401
-5.00%
-0.0179
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 1d ago
Weekly Report: what happened at CODX last week (0324-0328)?
Weekly Report · 3d ago
Co-Diagnostics Earnings Call: Progress Amid Challenges
TipRanks · 5d ago
Co-Diagnostics Is Maintained at Neutral by HC Wainwright & Co.
Dow Jones · 5d ago
Co-Diagnostics Price Target Cut to $1.00/Share From $1.50 by HC Wainwright & Co.
Dow Jones · 5d ago
HC Wainwright & Co. Maintains Neutral on Co-Diagnostics, Lowers Price Target to $1
Benzinga · 5d ago
Co-Diagnostics Faces Financial Challenges and Strategic Adjustments Amid Regulatory Setbacks
TipRanks · 6d ago
Co-Diagnostics price target lowered to $1 from $1.50 at H.C. Wainwright
TipRanks · 6d ago
Co-Diagnostics Reports 2024 Financial Results and Strategic Progress
TipRanks · 6d ago
Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates
NASDAQ · 6d ago
Co-Diagnostics targets 2025 clinical evaluations for TB and HPV tests in India and South Africa
Seeking Alpha · 6d ago
Co-Diagnostics Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 6d ago
Based on the provided financial report articles, I generated the title for the article: **"Codex Pharmaceuticals, Inc. (CODX) Reports Financial Results for Fiscal Year 2024 and Provides Business Update"** Please note that the title may not be exact, as the provided text does not contain a clear title. However, based on the content, I inferred the title to be related to the financial results of Codex Pharmaceuticals, Inc. (CODX) for Fiscal Year 2024 and a business update.
Press release · 6d ago
Co-Diagnostics FY 2024 GAAP EPS $(1.24) Misses $(1.22) Estimate, Sales $3.900M Miss $4.141M Estimate
Benzinga · 6d ago
*Co-Diagnostics 2024 Loss/Shr $1.24 >CODX
Dow Jones · 6d ago
*Co-Diagnostics 2024 Rev $3.9M >CODX
Dow Jones · 6d ago
Co-Diagnostics GAAP EPS of -$1.24 misses by $0.02, revenue of $3.91M misses by $0.23M
Seeking Alpha · 6d ago
CO-DIAGNOSTICS, INC. REPORTS FULL YEAR 2024 FINANCIAL RESULTS
Reuters · 6d ago
Press Release: Co-Diagnostics, Inc. Reports Full -2-
Dow Jones · 6d ago
Press Release: Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results
Dow Jones · 6d ago
More
Webull provides a variety of real-time CODX stock news. You can receive the latest news about Co-Diagnostics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CODX
More
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.